Ardelyx (NASDAQ:ARDX) Shares Gap Down After Earnings Miss

Ardelyx, Inc. (NASDAQ:ARDX) gapped down before the market opened on Friday following a weaker than expected earnings announcement. The stock had previously closed at $6.33, but opened at $6.00. Ardelyx shares last traded at $6.5010, with a volume of 1,889,510 shares.

The biopharmaceutical company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02). Ardelyx had a negative return on equity of 40.63% and a negative net margin of 15.12%.The firm had revenue of $94.47 million for the quarter, compared to analysts’ expectations of $92.78 million. During the same quarter last year, the company posted ($0.17) EPS. The firm’s revenue was up 27.5% on a year-over-year basis.

Key Stories Impacting Ardelyx

Here are the key news stories impacting Ardelyx this week:

• Positive Sentiment: Q1 revenue and product growth beat expectations: total revenue (~$94.5M) and product revenue (~$93.4M) rose strongly year‑over‑year, with IBSRELA sales up ~58% YoY; management reiterated 2026 revenue guidance of $410–$430M and reported a healthy cash balance (~$238M), supporting commercialization and runway. Ardelyx Reports First Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Unusual options flow: a large spike in call buying (7,048 calls, ~267% above typical volume) signals short‑term bullish sentiment from traders/hedgers, which can amplify upside momentum in the shares.
• Neutral Sentiment: Management emphasized strategic investments and commercialization execution on the earnings call — uses of cash and investment pacing matter for near‑term profits but aim to drive longer‑term growth. Ardelyx Inc (ARDX) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Investments
• Neutral Sentiment: The full earnings call transcript provides detail on channel trends, international plans and R&D spend — useful for investors assessing sustainability of revenue and timing of margin improvement. Ardelyx, Inc. (ARDX) Q1 2026 Earnings Call Transcript
• Negative Sentiment: EPS missed estimates: GAAP loss of $0.15/sh vs. consensus loss of $0.13, and the company still reports negative net margin and ROE; continuing operating losses keep near‑term profitability uncertain and may limit analyst upgrades. Ardelyx (ARDX) Reports Q1 Loss, Beats Revenue Estimates
• Negative Sentiment: Despite top‑line strength, the EPS miss and negative profitability metrics mean upside depends on continued sales acceleration, margin improvement and execution vs. guidance; any slowdown could pressure the share price. Ardelyx: Q1 Earnings Snapshot

Analysts Set New Price Targets

Several analysts recently weighed in on ARDX shares. Jefferies Financial Group restated a “buy” rating and issued a $15.00 price target on shares of Ardelyx in a research note on Tuesday, January 27th. Citigroup upped their price target on Ardelyx from $11.00 to $14.00 and gave the stock a “buy” rating in a research note on Friday, January 9th. Piper Sandler upgraded Ardelyx from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $10.00 to $16.00 in a research note on Thursday, January 8th. Raymond James Financial restated a “strong-buy” rating and issued a $19.00 price target on shares of Ardelyx in a research note on Thursday, January 8th. Finally, Wedbush restated an “outperform” rating and issued a $19.00 price target on shares of Ardelyx in a research note on Monday, February 23rd. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Ardelyx currently has an average rating of “Moderate Buy” and an average target price of $15.70.

Insider Activity

In other news, insider Eric Duane Foster sold 10,439 shares of the stock in a transaction on Friday, February 20th. The stock was sold at an average price of $5.85, for a total transaction of $61,068.15. Following the transaction, the insider directly owned 425,970 shares of the company’s stock, valued at $2,491,924.50. This represents a 2.39% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Mike Kelliher sold 9,595 shares of the stock in a transaction on Friday, February 20th. The shares were sold at an average price of $5.85, for a total value of $56,130.75. Following the transaction, the insider directly owned 364,666 shares in the company, valued at $2,133,296.10. The trade was a 2.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 128,604 shares of company stock worth $751,917. Insiders own 4.80% of the company’s stock.

Institutional Investors Weigh In On Ardelyx

Hedge funds and other institutional investors have recently modified their holdings of the stock. First Horizon Corp increased its stake in shares of Ardelyx by 120.4% in the 4th quarter. First Horizon Corp now owns 7,906 shares of the biopharmaceutical company’s stock worth $46,000 after purchasing an additional 4,319 shares in the last quarter. SBI Securities Co. Ltd. increased its stake in shares of Ardelyx by 147.0% in the 3rd quarter. SBI Securities Co. Ltd. now owns 10,253 shares of the biopharmaceutical company’s stock worth $56,000 after purchasing an additional 6,102 shares in the last quarter. Swiss Life Asset Management Ltd purchased a new stake in shares of Ardelyx in the 3rd quarter worth $57,000. Sumitomo Mitsui Trust Group Inc. purchased a new stake in shares of Ardelyx in the 4th quarter worth $60,000. Finally, State of Wyoming purchased a new stake in shares of Ardelyx in the 2nd quarter worth $61,000. 58.92% of the stock is currently owned by hedge funds and other institutional investors.

Ardelyx Price Performance

The company has a current ratio of 4.31, a quick ratio of 4.11 and a debt-to-equity ratio of 1.21. The stock has a market capitalization of $1.65 billion, a PE ratio of -26.71 and a beta of 0.66. The firm has a 50 day moving average price of $6.02 and a 200 day moving average price of $6.14.

About Ardelyx

Ardelyx, Inc (NASDAQ: ARDX) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio‐renal and gastrointestinal diseases. The company’s lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx’s proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.

Beyond tenapanor, Ardelyx’s development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders.